Srivastava’s group and others beautifully showed that those APCs are able to cross-present tumour antigens from HSP complexes to CD8+ T cells via MHC class I and thus elicit tumour-specific CD8+ T cell responses [44–46]. This evidence concerns the gene CD8A and neoplasm.